Skip to main content

News

The Inflammation Reflex (5.20.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Biologic Persistence in Psoriatic Arthritis and Psoriasis

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

Inflammatory Arthritis Spread by ATP and Neural Crosstalk

A novel study from the Journal of Experimental Medicine suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk.

Relevance of Raynaud’s in Systemic Sclerosis

Raynaud’s phenomenon (RP) is integral to the diagnosis and management of systemic sclerosis (SSc) patients; a recent analysis suggests that RP should be characterized based on color change and the presence of other symptoms to know whether RP portends more serious manifestations.

RNL 2022: Spondyloarthritis Spectrum

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.

- Microbiome in Spondyloathritis - Jose Scher, MD

- Axial Psoriatic Arthritis - Philip Mease, MD

- Juvenile Spondyloathritis - Pamela Weiss, MD

Rising Incidence of Systemic Lupus Erythematosus

Data from Olmstead county, MN over the past four decades shows that the incidence and prevalence of systemic lupus erythematosus (SLE) is increasing.

SLE was diagnosed using the EULAR/ACR criteria and looked at patients seen between 1976–2018.

Multimorbidity Burden in Rheumatoid Arthritis

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.

Acute Inflammatory Responses Needed to Resolve Chronic Pain

Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.

Bimekizumab Development Delayed by FDA

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

Methotrexate Monitoring (5.13.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.

A Day in the Life: Consults with a Rheumatology Fellow

MedPage Today

Join medical resident Siobhan Deshauer, MD, as she visits three hospitals for inpatient rheumatology.

Can You Reduce Frequency of Methotrexate Monitoring?

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.
×